BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15781636)

  • 1. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
    Symowicz J; Adley BP; Woo MM; Auersperg N; Hudson LG; Stack MS
    Cancer Res; 2005 Mar; 65(6):2234-42. PubMed ID: 15781636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.
    Fishman DA; Liu Y; Ellerbroek SM; Stack MS
    Cancer Res; 2001 Apr; 61(7):3194-9. PubMed ID: 11306508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; RosanĂ² L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
    Bian D; Su S; Mahanivong C; Cheng RK; Han Q; Pan ZK; Sun P; Huang S
    Cancer Res; 2004 Jun; 64(12):4209-17. PubMed ID: 15205333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
    Jeong KJ; Park SY; Seo JH; Lee KB; Choi WS; Han JW; Kang JK; Park CG; Kim YK; Lee HY
    Exp Mol Med; 2008 Dec; 40(6):607-16. PubMed ID: 19116446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms.
    Lin CI; Chen CN; Huang MT; Lee SJ; Lin CH; Chang CC; Lee H
    Cell Signal; 2008 Oct; 20(10):1804-14. PubMed ID: 18627789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells.
    Do TV; Symowicz JC; Berman DM; Liotta LA; Petricoin EF; Stack MS; Fishman DA
    Mol Cancer Res; 2007 Feb; 5(2):121-31. PubMed ID: 17314270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.
    So J; Navari J; Wang FQ; Fishman DA
    Gynecol Oncol; 2004 Nov; 95(2):314-22. PubMed ID: 15491751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.
    Wang FQ; So J; Reierstad S; Fishman DA
    Int J Cancer; 2005 Mar; 114(1):19-31. PubMed ID: 15523695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
    Gschwind A; Prenzel N; Ullrich A
    Cancer Res; 2002 Nov; 62(21):6329-36. PubMed ID: 12414665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
    Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
    Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
    Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
    Kang S; Luo R; Smicun Y; Fishman DA; Meng Y
    FEBS Lett; 2006 Jan; 580(2):443-9. PubMed ID: 16376882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion.
    Wang FQ; Smicun Y; Calluzzo N; Fishman DA
    Mol Cancer Res; 2006 Nov; 4(11):831-41. PubMed ID: 17114341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
    Cao Z; Liu LZ; Dixon DA; Zheng JZ; Chandran B; Jiang BH
    Cell Signal; 2007 Jul; 19(7):1542-53. PubMed ID: 17341442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
    Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM
    Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells.
    Goppelt-Struebe M; Fickel S; Reiser CO
    Biochem J; 2000 Jan; 345 Pt 2(Pt 2):217-24. PubMed ID: 10620497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
    Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.